DXCM Quote, Financials, Valuation and Earnings

BioLife Solutions, Inc. has a net margin of 21.22% compared to DexCom, Inc.'s net margin of 2.21%. DexCom, Inc.'s return on equity of 33.68% beat BioLife Solutions, Inc.'s return on equity of -5.11%.

DexCom, Inc. has a consensus price target of $85.46, signalling upside risk potential of 17.39%. On the other hand BioLife Solutions, Inc. has an analysts' consensus of $32.44 which suggests that it could grow by 42.05%. Given that BioLife Solutions, Inc. has higher upside potential than DexCom, Inc., analysts believe BioLife Solutions, Inc. is more attractive than DexCom, Inc..

DexCom, Inc. has a beta of 1.491, which suggesting that the stock is 49.074% more volatile than S&P 500. In comparison BioLife Solutions, Inc. has a beta of 1.924, suggesting its more volatile than the S&P 500 by 92.426%.

DexCom, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BioLife Solutions, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. DexCom, Inc. pays -- of its earnings as a dividend. BioLife Solutions, Inc. pays out -- of its earnings as a dividend.

DexCom, Inc. quarterly revenues are $1.3B, which are larger than BioLife Solutions, Inc. quarterly revenues of $28.1M. DexCom, Inc.'s net income of $267.3M is higher than BioLife Solutions, Inc.'s net income of $621K. Notably, DexCom, Inc.'s price-to-earnings ratio is 34.78x while BioLife Solutions, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for DexCom, Inc. is 6.33x versus 10.93x for BioLife Solutions, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Boston Scientific Corp. has a net margin of 21.22% compared to DexCom, Inc.'s net margin of 12.68%. DexCom, Inc.'s return on equity of 33.68% beat Boston Scientific Corp.'s return on equity of 12.55%.

DexCom, Inc. has a consensus price target of $85.46, signalling upside risk potential of 17.39%. On the other hand Boston Scientific Corp. has an analysts' consensus of $104.78 which suggests that it could grow by 37.36%. Given that Boston Scientific Corp. has higher upside potential than DexCom, Inc., analysts believe Boston Scientific Corp. is more attractive than DexCom, Inc..

DexCom, Inc. has a beta of 1.491, which suggesting that the stock is 49.074% more volatile than S&P 500. In comparison Boston Scientific Corp. has a beta of 0.666, suggesting its less volatile than the S&P 500 by 33.441%.

DexCom, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Boston Scientific Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. DexCom, Inc. pays -- of its earnings as a dividend. Boston Scientific Corp. pays out -- of its earnings as a dividend.

DexCom, Inc. quarterly revenues are $1.3B, which are smaller than Boston Scientific Corp. quarterly revenues of $5.3B. DexCom, Inc.'s net income of $267.3M is lower than Boston Scientific Corp.'s net income of $670M. Notably, DexCom, Inc.'s price-to-earnings ratio is 34.78x while Boston Scientific Corp.'s PE ratio is 39.34x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for DexCom, Inc. is 6.33x versus 5.68x for Boston Scientific Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Krystal Biotech, Inc. has a net margin of 21.22% compared to DexCom, Inc.'s net margin of 47.99%. DexCom, Inc.'s return on equity of 33.68% beat Krystal Biotech, Inc.'s return on equity of 19.22%.

DexCom, Inc. has a consensus price target of $85.46, signalling upside risk potential of 17.39%. On the other hand Krystal Biotech, Inc. has an analysts' consensus of $306.56 which suggests that it could grow by 8.21%. Given that DexCom, Inc. has higher upside potential than Krystal Biotech, Inc., analysts believe DexCom, Inc. is more attractive than Krystal Biotech, Inc..

DexCom, Inc. has a beta of 1.491, which suggesting that the stock is 49.074% more volatile than S&P 500. In comparison Krystal Biotech, Inc. has a beta of 0.493, suggesting its less volatile than the S&P 500 by 50.719%.

DexCom, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Krystal Biotech, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. DexCom, Inc. pays -- of its earnings as a dividend. Krystal Biotech, Inc. pays out -- of its earnings as a dividend.

DexCom, Inc. quarterly revenues are $1.3B, which are larger than Krystal Biotech, Inc. quarterly revenues of $107.1M. DexCom, Inc.'s net income of $267.3M is higher than Krystal Biotech, Inc.'s net income of $51.4M. Notably, DexCom, Inc.'s price-to-earnings ratio is 34.78x while Krystal Biotech, Inc.'s PE ratio is 41.39x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for DexCom, Inc. is 6.33x versus 21.79x for Krystal Biotech, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Sotera Health Co. has a net margin of 21.22% compared to DexCom, Inc.'s net margin of 15.55%. DexCom, Inc.'s return on equity of 33.68% beat Sotera Health Co.'s return on equity of 11.79%.

DexCom, Inc. has a consensus price target of $85.46, signalling upside risk potential of 17.39%. On the other hand Sotera Health Co. has an analysts' consensus of $20.44 which suggests that it could grow by 17.12%. Given that DexCom, Inc. has higher upside potential than Sotera Health Co., analysts believe DexCom, Inc. is more attractive than Sotera Health Co..

DexCom, Inc. has a beta of 1.491, which suggesting that the stock is 49.074% more volatile than S&P 500. In comparison Sotera Health Co. has a beta of 1.819, suggesting its more volatile than the S&P 500 by 81.894%.

DexCom, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sotera Health Co. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. DexCom, Inc. pays -- of its earnings as a dividend. Sotera Health Co. pays out -- of its earnings as a dividend.

DexCom, Inc. quarterly revenues are $1.3B, which are larger than Sotera Health Co. quarterly revenues of $311.3M. DexCom, Inc.'s net income of $267.3M is higher than Sotera Health Co.'s net income of $48.4M. Notably, DexCom, Inc.'s price-to-earnings ratio is 34.78x while Sotera Health Co.'s PE ratio is 90.41x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for DexCom, Inc. is 6.33x versus 4.33x for Sotera Health Co.. Usually stocks with elevated PS ratios are considered overvalued.